The DOI matches its Crossref record; 175 of the 175 references it cites were found in a registry or an index.
A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer
Abstract
Breast cancer (BC) is one of the most prevalent cancers in women. Triple-negative breast cancer (TNBC) in which the three major receptors i.e. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are absent is known to express the most aggressive phenotype and increased metastasis which results in the development of resistance to chemotherapy. It offers various therapeutic advantages in treating BC and TNBC. Nanotechnology offers various unique characteristics such as small size (nanometric), active and passive targeting, and the ability to attach multiple targeting moieties, controlled release, and site-specific targeting. This review focuses on conventional drug therapies, recent treatment strategies, and unique therapeutic approaches available for BC and TNBC. The role of breast cancer stem cells in the recurrence of BC and TNBC has also been highlighted. Several chemotherapeutic agents delivered using nanocarriers such as polymeric nanoparticles/micelles, metallic/inorganic NPs, and lipid-based NPs (Liposome, solid-lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)), etc. with excellent responses in the treatment of BC/TNBC along with breast cancer stem cells have been discussed in details. Moreover, the application of nanomedicine including CRISPR nanoparticle, exosomes for the treatment of BC/TNBC and other molecular targets available such as poly (ADP-ribose) polymerase (PARP), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), etc. for further exploration have also been discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pal, K., Roy, S., Parida, P. K., Dutta, A., Bardhan, S., Das, S., Jana, K., & Karmakar, P. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.10.071 · Cited by 116
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Metastatic colonization by circulating tumour cells
Massagué, J., & Obenauf, A. C. (2016) · Nature · doi:10.1038/nature17038 · Cited by 2,062
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Breast cancer statistics, 2017, racial disparity in mortality by state
DeSantis, C. E., Ma, J., Goding Sauer, A., Newman, L. A., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21412 · Cited by 1,879
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., Wei, J., & Nie, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.083 · Cited by 1,801
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
Liu, S., Cong, Y., Wang, D., Sun, Y., Deng, L., Liu, Y., Martin-Trevino, R., Shang, L., McDermott, S. P., Landis, M. D., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.11.009 · Cited by 1,053
Self-Assembled Lipid−Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform
Zhang, L., Chan, J. M., Gu, F. X., Rhee, J.-W., Wang, A. Z., Radovic-Moreno, A. F., Alexis, F., Langer, R., & Farokhzad, O. C. (2008) · ACS Nano · doi:10.1021/nn800275r · Cited by 1,038
Kobayashi, H., Watanabe, R., & Choyke, P. L. (2014) · Theranostics · doi:10.7150/thno.7193 · Cited by 996
Breast-Cancer Screening — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., & Straif, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1504363 · Cited by 962
Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 876
Wang, T., Fahrmann, J. F., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., Zhang, C., Lifshitz, V., Song, J., Yuan, Y., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.001 · Cited by 825
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0141 · Cited by 801
Mesoporous silica nanoparticles in medicine—Recent advances
Mamaeva, V., Sahlgren, C., & Lindén, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 707
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy
Palmerston Mendes, L., Pan, J., & Torchilin, V. (2017) · Molecules · doi:10.3390/molecules22091401 · Cited by 701
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., & Wender, R. C. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21557 · Cited by 701
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., et al. (2013) · ACS Nano · doi:10.1021/nn3044066 · Cited by 575
Genistein and Cancer: Current Status, Challenges, and Future Directions
Spagnuolo, C., Russo, G. L., Orhan, I. E., Habtemariam, S., Daglia, M., Sureda, A., Nabavi, S. F., Devi, K. P., Loizzo, M. R., Tundis, R., et al. (2015) · Advances in Nutrition · doi:10.3945/an.114.008052 · Cited by 557
In Vivo Biodistribution and Toxicology of Carboxylated Graphene Quantum Dots
Nurunnabi, M., Khatun, Z., Huh, K. M., Park, S. Y., Lee, D. Y., Cho, K. J., & Lee, Y.-K. (2013) · ACS Nano · doi:10.1021/nn402043c · Cited by 546
An overview on the role of dietary phenolics for the treatment of cancers
Anantharaju, P. G., Gowda, P. C., Vimalambike, M. G., & Madhunapantula, S. V. (2016) · Nutrition Journal · doi:10.1186/s12937-016-0217-2 · Cited by 517
Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 496
Targeted therapy using nanotechnology: focus on cancer
Sechi, M., Sanna, V., & Pala, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s36654 · Cited by 493
Peng, F., Setyawati, M. I., Tee, J. K., Ding, X., Wang, J., Nga, M. E., Ho, H. K., & Leong, D. T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0356-z · Cited by 480
Cancer Stem Cells and Drug Resistance: The Potential of Nanomedicine
Vinogradov, S., & Wei, X. (2012) · Nanomedicine · doi:10.2217/nnm.12.22 · Cited by 474
Liposome-based drug delivery in breast cancer treatment
Park, J. W. (2002) · Breast Cancer Research · doi:10.1186/bcr432 · Cited by 469
Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis
Zhao, L., Gu, C., Gan, Y., Shao, L., Chen, H., & Zhu, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.005 · Cited by 438
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Radiation‐Induced Reprogramming of Breast Cancer Cells
Lagadec, C., Vlashi, E., Della Donna, L., Dekmezian, C., & Pajonk, F. (2012) · STEM CELLS · doi:10.1002/stem.1058 · Cited by 401
Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer
Singh, R., Pochampally, R., Watabe, K., Lu, Z., & Mo, Y.-Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-256 · Cited by 399
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer
Gurunathan, S., Kang, M.-H., Qasim, M., & Kim, J.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103264 · Cited by 367
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Bioactive natural products in cancer prevention and therapy: Progress and promise
Bishayee, A., & Sethi, G. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.006 · Cited by 354
Arm problems and psychological distress after surgery for breast cancer.
Maunsell, E., Brisson, J., & Deschěnes, L. (1993) · PubMed · Cited by 352
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Heparanase, Hyaluronan, and CD44 in Cancers: A Breast Carcinoma Perspective
Götte, M., & Yip, G. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1464 · Cited by 340
Chen, Z., Liu, F., Chen, Y., Liu, J., Wang, X., Chen, A. T., Deng, G., Zhang, H., Liu, J., Hong, Z., et al. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703036 · Cited by 297
Krop, I. E., Mayer, I. A., Ganju, V., Dickler, M., Johnston, S., Morales, S., Yardley, D. A., Melichar, B., Forero-Torres, A., Lee, S. C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00106-6 · Cited by 295
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 274
Quercetin-nanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro
Sun, M., Nie, S., Pan, X., Zhang, R., Fan, Z., & Wang, S. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.08.032 · Cited by 263
Neoadjuvant treatment of breast cancer
Thompson, A. M., & Moulder-Thompson, S. L. (2012) · Annals of Oncology · doi:10.1093/annonc/mds324 · Cited by 251
Suh, Y., Afaq, F., Johnson, J. J., & Mukhtar, H. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn269 · Cited by 251
Loman, N., Johannsson, O., Kristoffersson, U., Olsson, H., & Borg, A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1215 · Cited by 248
Nahum, A., Hirsch, K., Danilenko, M., Watts, C. K., Prall, O. W., Levy, J., & Sharoni, Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204452 · Cited by 235
Jain, A. K., Thanki, K., & Jain, S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400311j · Cited by 235
Fiorillo, M., Verre, A. F., Iliut, M., Peiris-Pagés, M., Ozsvari, B., Gandara, R., Cappello, A. R., Sotgia, F., Vijayaraghavan, A., & Lisanti, M. P. (2015) · Oncotarget · doi:10.18632/oncotarget.3348 · Cited by 234
Deng, J., Xu, S., Hu, W., Xun, X., Zheng, L., & Su, M. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.048 · Cited by 234
Burke, A. R., Singh, R. N., Carroll, D. L., Wood, J. C. S., D’Agostino, R. B., Ajayan, P. M., Torti, F. M., & Torti, S. V. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.052 · Cited by 227
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Finn, R. S., Bengala, C., Ibrahim, N., Roché, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0288 · Cited by 220
Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy
Zhang, L., Wang, P., Feng, Q., Wang, N., Chen, Z., Huang, Y., Zheng, W., & Jiang, X. (2017) · NPG Asia Materials · doi:10.1038/am.2017.185 · Cited by 218
Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor
Liu, Y., Chen, C., Qian, P., Lu, X., Sun, B., Zhang, X., Wang, L., Gao, X., Li, H., Chen, Z., et al. (2015) · Nature Communications · doi:10.1038/ncomms6988 · Cited by 202
Berrino, F., Bellati, C., Secreto, G., Camerini, E., Pala, V. M., Panico, S., Allegro, G., & Kaaks, R. (2001) · PubMed · Cited by 198
Shi, J., Xiao, Z., Votruba, A. R., Vilos, C., & Farokhzad, O. C. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101554 · Cited by 196
Januškevičienė, I., & Petrikaitė, V. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117009 · Cited by 196
Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., Bondarenko, I., Citrin, D., Campone, M., Telli, M. L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx505 · Cited by 194
Aptamer-Modified Tetrahedral DNA Nanostructure for Tumor-Targeted Drug Delivery
Li, Q., Zhao, D., Shao, X., Lin, S., Xie, X., Liu, M., Ma, W., Shi, S., & Lin, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b13328 · Cited by 187
Adhami, V. M., Syed, D. N., Khan, N., & Mukhtar, H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.012 · Cited by 186
Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds
Sun, T.-M., Wang, Y.-C., Wang, F., Du, J.-Z., Mao, C.-Q., Sun, C.-Y., Tang, R.-Z., Liu, Y., Zhu, J., Zhu, Y.-H., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.011 · Cited by 174
Mimeault, M., Hauke, R., & Batra, S. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100296 · Cited by 168
Han, M., Lv, Q., Tang, X.-J., Hu, Y.-L., Xu, D.-H., Li, F.-Z., Liang, W.-Q., & Gao, J.-Q. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.020 · Cited by 167
Alarming Burden of Triple-Negative Breast Cancer in India
Thakur, K. K., Bordoloi, D., & Kunnumakkara, A. B. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.07.013 · Cited by 167
Bhatnagar, S., Bankar, N. G., Kulkarni, M. V., & Venuganti, V. V. K. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.022 · Cited by 165
Parvani, J. G., Gujrati, M. D., Mack, M. A., Schiemann, W. P., & Lu, Z.-R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3485 · Cited by 159
Anhorn, M. G., Wagner, S., Kreuter, J., Langer, K., & von Briesen, H. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8002452 · Cited by 157
The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles
Lee, A. L. Z., Wang, Y., Cheng, H. Y., Pervaiz, S., & Yang, Y. Y. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.10.062 · Cited by 157
Jain, A., Sharma, G., Ghoshal, G., Kesharwani, P., Singh, B., Shivhare, U. S., & Katare, O. P. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.04.061 · Cited by 156
PARP inhibitors: the race is on
Brown, J. S., Kaye, S. B., & Yap, T. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.67 · Cited by 149
Zhu, P., Wang, Y., Du, Y., He, L., Huang, G., Zhang, G., Yan, X., & Fan, Z. (2015) · Nature Communications · doi:10.1038/ncomms8122 · Cited by 146
Murugan, C., Rayappan, K., Thangam, R., Bhanumathi, R., Shanthi, K., Vivek, R., Ramasamy, T., Bhattacharyya, A., Sivasubramanian, S., Gunasekaran, P., et al. (2016) · Scientific Reports · doi:10.1038/srep34053 · Cited by 144
Kutty, R. V., & Feng, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.043 · Cited by 142
Telli, M. L., Hellyer, J. A., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., Gutin, A., Abkevich, V., Peterson, R. N., Neff, C. D., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4624-7 · Cited by 138
Thipe, V. C., Amiri, K. P., Bloebaum, P., Raphael, A. K., Khoobchandani, M., Katti, K. K., Jurisson, S. S., & Katti, K. V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s204443 · Cited by 138
Anticancer Effects of Resveratrol-Loaded Solid Lipid Nanoparticles on Human Breast Cancer Cells
Wang, W., Zhang, L., Chen, T., Guo, W. Z., Bao, X., Wang, D., Ren, B., Wang, H., Li, Y., Wang, Y., et al. (2017) · Molecules · doi:10.3390/molecules22111814 · Cited by 135
Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy
Jain, V. K., Swarnakar, N. K., Mishra, P. R., Verma, A., Kaul, A., Mishra, A. K., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.056 · Cited by 133
Self-citationZuo, Z.-Q., Chen, K., Yu, X., Zhao, G., Shen, S., Cao, Z., Luo, Y., Wang, Y., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.014 · Cited by 131
Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance
Zhao, Y., Huan, M., Liu, M., Cheng, Y., Sun, Y., Cui, H., Liu, D., Mei, Q., & Zhou, S. (2016) · Scientific Reports · doi:10.1038/srep35267 · Cited by 130
Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy
Meric‐Bernstam, F., & Hung, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1732 · Cited by 129
Li, S.-Y., Sun, R., Wang, H., Shen, S., Liu, Y., Du, X., Zhu, Y., & Jun, W. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.011 · Cited by 128
Yu, Z., Ni, M., Xiong, M., Zhang, X., Cai, G., Chen, H., & Zeng, Q. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s78498 · Cited by 127
Cancer nanomedicine: Addressing the dark side of the enhanced permeability and retention effect
Huynh, E., & Zheng, G. (2015) · Nanomedicine · doi:10.2217/nnm.15.86 · Cited by 125
Liposomes as targetable drug carriers.
Torchilin, V. P. (1985) · PubMed · Cited by 125
Rokade, S. S., Joshi, K. A., Mahajan, K., Patil, S., Tomar, G. B., Dubal, D., Parihar, V. S., Kitture, R., Bellare, J., & Ghosh, S. (2018) · Bioinorganic Chemistry and Applications · doi:10.1155/2018/4924186 · Cited by 122
Feng, C., Yuan, X., Chu, K., Zhang, H., Ji, W., & Rui, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.003 · Cited by 119
Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods
Souto, E. B., Silva, G. F., Dias-Ferreira, J., Zielińska, A., Ventura, F. V., Durazzo, A., Lucarini, M., Novellino, E., & Santini, A. (2020) · Nanomaterials · doi:10.3390/nano10030455 · Cited by 119
Singh, A., Neupane, Y. R., Panda, B. P., & Kohli, K. (2017) · Journal of Microencapsulation · doi:10.1080/02652048.2017.1340355 · Cited by 118
Lipid-based nanocarriers for breast cancer treatment – comprehensive review
Talluri, S. V., Kuppusamy, G., Karri, V. V. S. R., Tummala, S., & Madhunapantula, S. V. (2015) · Drug Delivery · doi:10.3109/10717544.2015.1092183 · Cited by 117
Wu, L., Jingling, Na, N., Hongyu, Hongmei, & Zhiyong (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s24185 · Cited by 116
Lahmann, P. H., Lissner, L., Gullberg, B., Olsson, H. L., & Berglund, G. L. (2002) · International Journal of Cancer · doi:10.1002/ijc.10799 · Cited by 116
Mei, L., Zhang, H., Zeng, X., Huang, L., Wang, Z., Liu, G., Wu, Y., & Yang, C. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s78988 · Cited by 114
Valicherla, G. R., Dave, K. M., Syed, A. A., Riyazuddin, M., Gupta, A. P., Singh, A., Wahajuddin, M., Mitra, K., Datta, D. B., & Gayen, J. R. (2016) · Scientific Reports · doi:10.1038/srep26895 · Cited by 110
Pandey, S. K., Patel, D. K., Thakur, R. K., Mishra, D. P., Maiti, P., & Haldar, C. (2015) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2015.02.011 · Cited by 108
Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells
Gupta, U. D., Dwivedi, S. K. D., Bid, H. K., Konwar, R., & Jain, N. K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.002 · Cited by 107
Immune Checkpoint Blockade for Breast Cancer
Swoboda, A. T., & Nanda, R. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_10 · Cited by 106
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells
He, L., Gu, J. H., Lim, L. Y., Yuan, Z., & Mo, J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00313 · Cited by 101
Targeted Therapies in Triple-Negative Breast Cancer
Marmé, F., & Schneeweiß, A. (2015) · Breast Care · doi:10.1159/000433622 · Cited by 100
Chemical approaches to targeting drug resistance in cancer stem cells
Sotiropoulou, P. A., Christodoulou, M. S., Silvani, A., Herold-Mende, C., & Passarella, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.05.002 · Cited by 100
Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs
Mao, L., Li, J., Chen, W., Cai, Y.-Q., Yu, D., Zhong, S., Zhao, J., Zhou, J., & Tang, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4402-2 · Cited by 100
Ayoub, N. M., Al-Shami, K. M., & Yaghan, R. J. (2019) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s175360 · Cited by 100
Advances in the use of nanocarriers for cancer diagnosis and treatment
Vieira, D. B., & Gamarra, L. F. (2016) · Einstein (São Paulo) · doi:10.1590/s1679-45082016rb3475 · Cited by 99
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Chen, Y., & Zhang, Y. (2018) · Advanced Science · doi:10.1002/advs.201700964 · Cited by 99
In Situ shRNA Synthesis on DNA–Polylactide Nanoparticles to Treat Multidrug Resistant Breast Cancer
Ni, Q., Zhang, F., Zhang, Y., Zhu, G., Wang, Z., Teng, Z., Wang, C., Yung, B. C., Niu, G., Lu, G., et al. (2018) · Advanced Materials · doi:10.1002/adma.201705737 · Cited by 96
Lipid-Based Nanoparticles in Cancer Diagnosis and Therapy
Miller, A. D. (2013) · Journal of Drug Delivery · doi:10.1155/2013/165981 · Cited by 93
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
Chalakur-Ramireddy, N. K. R., & Pakala, S. B. (2018) · Bioscience Reports · doi:10.1042/bsr20171357 · Cited by 92
Natural Bioactives in Cancer Treatment and Prevention
Hsieh, Y., Yang, S., Sethi, G., et al. (2015) · BioMed Research International · doi:10.1155/2015/182835 · Cited by 89
CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition
Chittasupho, C., Anuchapreeda, S., & Sarisuta, N. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.07.003 · Cited by 87
Non-coding RNAs as potential therapeutic targets in breast cancer
Tomar, D., Yadav, A. S., Kumar, D., Bhadauriya, G., & Kundu, G. C. (2019) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.04.005 · Cited by 86
Wang, Y., Shi, K., Zhang, L., Hu, G., Wan, J., Tang, J., Yin, S., Duan, J., Qin, M., Wang, N., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1162930 · Cited by 84
Clinical and molecular aspects of breast cancer: Targets and therapies
Godone, R. L. N., Leitão, G. M., Araújo, N., Castelletti, C. H. M., de Lima-Filho, J. L., & Martins, D. B. G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.066 · Cited by 83
How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment
Saraiva, D. P., Cabral, M. G., Jacinto, A., & Braga, S. A. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000208 · Cited by 81
Luo, J., Wang, P., Wang, R., Wang, J., Liu, M., Xiong, S., Li, Y., & Cheng, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6672 · Cited by 80
Guo, X., Zhao, Z., Chen, D., Qiao, M., Wan, F., Cun, D., Sun, Y., & Yang, M. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.03.002 · Cited by 80
Cellular delivery of PEGylated PLGA nanoparticles
Pamujula, S., Hazari, S., Bolden, G., Graves, R. A., Chinta, D. D., Dash, S., Kishore, V., & Mandal, T. K. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01376.x · Cited by 78
Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting
Lu, B., Huang, X., Mo, J., & Zhao, W. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00084 · Cited by 78
Verma, R. K., Yu, W., Singh, S. P., Shankar, S., & Srivastava, R. K. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.07.001 · Cited by 77
Phytochemicals: Current strategies for treating breast cancer (Review)
Israel, B., Tilghman, S. L., Lemieux, K. P., & Payton‐Stewart, F. (2018) · Oncology Letters · doi:10.3892/ol.2018.8304 · Cited by 77
Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer
Vogel, V. G. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181788d88 · Cited by 75
The Role of Magnetic Nanoparticles in the Localization and Treatment of Breast Cancer
Ahmed, M., & Douek, M. (2013) · BioMed Research International · doi:10.1155/2013/281230 · Cited by 75
Synthetic cannabinoids nano-micelles for the management of triple negative breast cancer
Greish, K. F., Mathur, A., Alzahrani, R., Elkaissi, S., Aljishi, M., Nazzal, O., Taha, S., Pittalà, V., & Taurin, S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.030 · Cited by 74
Nanomedicine and epigenome. Possible health risks
Smolková, B., Dušinská, M., & Gábelová, A. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.07.020 · Cited by 73
Paredes, K. O., Díaz‐García, D., García‐Almodóvar, V., Chamizo, L. L., Marciello, M., Díaz‐Sánchez, M., Prashar, S., Gómez‐Ruiz, S., & Filice, M. (2020) · Cancers · doi:10.3390/cancers12010187 · Cited by 73
Development and characterization of surface engineered PPI dendrimers for targeted drug delivery
Kaur, A., Jain, K., Mehra, N. K., & Jain, N. K. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2016.1160912 · Cited by 70
Kavithaa, K., Paulpandi, M., Padma, P. R., & Sumathi, S. (2016) · RSC Advances · doi:10.1039/c6ra11658b · Cited by 65
Gu, J., Fang, X., Hao, J., & Sha, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.030 · Cited by 64
How can nanotechnology help the fight against breast cancer?
Avitabile, E., Bedognetti, D., Ciofani, G., Bianco, A., & Delogu, L. G. (2018) · Nanoscale · doi:10.1039/c8nr02796j · Cited by 61
Wan, X., Liu, C., Lin, Y., Fu, J., Lu, G., & Lu, Z. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1576801 · Cited by 57
Multipotent luminal mammary cancer stem cells model tumor heterogeneity
Bao, L., Cardiff, R. D., Steinbach, P. A., Messer, K. S., & Ellies, L. G. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0615-y · Cited by 55
Sorolla, A., Wang, E., Clemons, T. D., Evans, C. W., Plani-Lam, J. H. C., Golden, E., Dessauvagie, B., Redfern, A. D., Swaminathan-Iyer, K., & Blancafort, P. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2019.04.006 · Cited by 54
Darvishi, B., Farahmand, L., & Majidzadeh‐A, K. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.03.007 · Cited by 53
Ahmad, A., Mondal, S. K., Mukhopadhyay, D., Banerjee, R., & Alkharfy, K. M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00900 · Cited by 49
Hernández-Delgadillo, R., García-Cuellar, C. M., Sánchez-Pérez, Y., Pineda‐Aguilar, N., Martínez-Martínez, M. A., Padilla, E. E. R., Nakagoshi-Cepeda, S. E., Solís-Soto, J. M., Sánchez-Najéra, R. I., Nakagoshi-Cepeda, M. A. A., et al. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s179095 · Cited by 49
Perlecan-Targeted Nanoparticles for Drug Delivery to Triple-Negative Breast Cancer
Khanna, V., Kalscheuer, S., Kirtane, A. R., Zhang, W., & Panyam, J. (2019) · Future Drug Discovery · doi:10.4155/fdd-2019-0005 · Cited by 49
Kondath, S., Raghavan, B. S., Rajaram, A., & Rajaram, R. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.09.025 · Cited by 47
Inhibiting metastasis of breast cancer cells in vitro using gold nanorod-siRNA delivery system
Zhang, W., Meng, J., Ji, Y., Li, X., Kong, H., Wu, X., & Xu, H. (2011) · Nanoscale · doi:10.1039/c1nr10573f · Cited by 47
Xue, Y., Tang, X., Huang, J. T., Zhang, X., Yu, J., Zhang, Y., & Gui, S. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.02.040 · Cited by 47
Liu, J., Li, J., Liu, N., Guo, N., Gao, C., Hao, Y., Chen, L., & Zhang, X. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.026 · Cited by 47
Li, J., Xu, W., Yuan, X., Chen, H., Song, H., Wang, B., & Han, J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s144184 · Cited by 47
Gao, H., Cao, S., Chen, C., Cao, S., Yang, Z. H., Pang, Z., Xi, Z., Pan, S., Zhang, Q., & Jiang, X. (2013) · Nanomedicine · doi:10.2217/nnm.12.180 · Cited by 44
Palma, G., Conte, C., Barbieri, A., Bimonte, S., Luciano, A., Rea, D., Ungaro, F., Tirino, P., Quaglia, F., & Arra, C. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.06.058 · Cited by 43
Rahman, S. M. M., Song, H. B., Jin, Y., Oh, J., Lim, M. K., Hong, S., & Choi, M. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005995 · Cited by 43
Antibody–Drug Conjugates in Triple Negative Breast Cancer
Tray, N., Adams, S., & Esteva, F. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0131 · Cited by 42
Timur, S. S., Yöyen-Ermiş, D., Esendağlı, G., Yonat, S., Horzum, U., Esendağlı, G., & Gürsoy, R. N. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.01.017 · Cited by 41
Liu, Y., Li, L., Qi, G., Chen, X., & Wang, H. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.12.089 · Cited by 40
Polymeric Nanocarriers: A New Horizon for the Effective Management of Breast Cancer
Khan, I., Kumar, H., Mishra, G., Gothwal, A., Kesharwani, P., & Gupta, U. D. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666170829164828 · Cited by 39
Self-citationNanocarrier based approaches for targeting breast cancer stem cells
Pindiprolu, S. K. S. S., Krishnamurthy, P. T., Chintamaneni, P. K., & Karri, V. V. S. R. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1366337 · Cited by 38
Tumor Twitter: Cellular Communication in the Breast Cancer Stem Cell Niche
Brooks, M. D., & Wicha, M. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0327 · Cited by 30
Zhang, Y., Lü, Y., Zhang, Y., He, X., Chen, Q., Liu, L., Chen, X., Ruan, C., Sun, T., & Jiang, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00430 · Cited by 26
Breast cancer: Lesser-known facets and hypotheses
Patel, S. V. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.087 · Cited by 25
Development of nanoparticulate systems with action in breast and ovarian cancer: nanotheragnostics
Cunha, F. D. S., Pereira, L. N. D. S., Silva, T. P. D. C. E., Luz, R. A. S., & Mendes, A. N. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1523418 · Cited by 19
Greten, F. R. (2017) · Nature · doi:10.1038/543626a · Cited by 18
Non-Platinum Metal Complexes as Potential Anti-Triple Negative Breast Cancer Agents
Domínguez-Martís, E. M., Mosteiro-Miguéns, D. G., Vigo-Gendre, L., López-Ares, D., Freire‐Garabal, M., Núñez-Iglesias, M. J., & Novío, S. (2018) · Crystals · doi:10.3390/cryst8100369 · Cited by 16
Clinical applications of nanostructured drug delivery systems
Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-102198-9.00004-1 · Cited by 13
Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer
Stover, D. G., Bell, C., & Tolaney, S. M. (2016) · American Journal of Hematology / Oncology® · Cited by 11
Ghosh, A., Bhowmik, A., Bhandary, S., Putatunda, S., Laskar, A., Biswas, A., Dolui, S., Banerjee, B., Khan, R., Das, N., et al. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.04.011 · Cited by 10
Novel Survivin-Targeted Small Interfering RNA Delivered by Nanoparticles
Feng, C., Wang, T., Zhang, Y., et al. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.08.002 · Cited by 5
Cited by
Zuo, S., Zhang, Y., Wang, Z., & Wang, J. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s348618 · Cited by 41
Metadata
- Authors
- Jain, V., Kumar, H., Anod, H. V., Chand, P., Gupta, N. V., Dey, S., & Kesharwani, S. S.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 326
- Pages
- 628-647
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W3041685607
- Cited by
- 290
- References
- 175
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.